Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Go back to Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 58.36 -0.13 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.49 | 52 Week High | $17.00 | |||
| Open | $58.28 | 52 Week Low | $3.55 | |||
| Day High | $59.15 | P/E | N/A | |||
| Day Low | $57.90 | EPS | $-1.33 | |||
| Volume | 5,243,437 | |||||
